AbbVie Drugs by Revenue Breakdown and Analysis

AbbVie's revenue breakdown is a fascinating topic, and one of the company's crown jewels is its Humira franchise, which generated over $20 billion in revenue in 2020.

Humira, a biologic medication used to treat autoimmune diseases, is AbbVie's top-selling drug and accounts for nearly 60% of the company's total revenue.

AbbVie's other notable revenue contributors include Imbruvica, a cancer treatment, and Venclexta, a leukemia medication, both of which have been growing rapidly in recent years.

The company's revenue growth is largely driven by its biologics portfolio, which includes Humira, Imbruvica, and Venclexta.

AbbVie's revenue breakdown is a complex picture, but let's break it down.

Immunology drugs like Rinvoq and Skyrizi drove AbbVie's top line, with net revenues from Rinvoq totaling $1.83 billion in the fourth quarter, up 47.1%.

Skyrizi sales also surged, with net revenues reaching $3.78 billion, a 57.9% increase. This growth was fueled by label expansions to include new patient populations in recent quarters.

Humira, AbbVie's flagship product, saw a decline of 48.7% to $1.68 billion in the fourth quarter. This substantial drop was due to the drug's loss of exclusivity in the United States since January 2023.

Neuroscience sales increased 19.9% to $2.51 billion, driven by higher sales of Botox Therapeutic, Vraylar, Ubrelvy, and Qulipta.

Here's a breakdown of AbbVie's revenue by therapy area for 2022-2024:

Note: The exact figures for 2022-2024 are not provided in the article sections, but this table gives you an idea of how AbbVie's revenue is distributed across different therapy areas.

AbbVie's oncology/hematology sales rose 12.9% to $1.69 billion in the quarter, driven by sales from Elahere and Venclexta, which more than offset the declining Imbruvica sales.

Epkinly sales, which comprise AbbVie's share of profit from U.S. revenues and product revenues from international markets, amounted to $40 million in the quarter compared with $43 million in the previous quarter.

Rinvoq was a top revenue-generating drug for AbbVie, with net revenues totaling $1.83 billion in the fourth quarter, up 47.1% from the previous quarter.

This significant growth can be attributed to label expansions of the drug to include new patient populations.

Skyrizi also saw a surge in sales, with net revenues reaching $3.78 billion, up 57.9% from the previous quarter.

The label expansions of Skyrizi to include new patient populations were the main driver of this increase in sales.

Humira, on the other hand, recorded a sales decline of 48.7% to $1.68 billion in the fourth quarter.

This substantial decline was due to the drug's loss of exclusivity in the United States since January 2023.

Botox Therapeutic sales rose 13% to $873 million, while Vraylar sales increased 17.1% to $924 million.

Ubrelvy sales totaled $303 million, up 29.6%, and Qulipta sales increased 76.2% to $201 million.

These neuroscience portfolio products drove the 19.9% increase in sales to $2.51 billion.

Here's a breakdown of AbbVie's top revenue-generating drugs:

These drugs were key contributors to AbbVie's revenue growth in the fourth quarter.

AbbVie's aesthetics portfolio saw a decline in sales, with Botox Cosmetic sales falling to $687 million, a 3.4% drop from previous numbers.

The aesthetics portfolio's overall sales were down 4.4% to $1.30 billion.

Juvederm sales, a key player in the aesthetics portfolio, declined 15.1% to $279 million.

On the other hand, the eye care portfolio experienced a significant increase in sales, rising 11.4% to $646 million.

Ozurdex, a key drug in the eye care portfolio, saw a modest increase of 1.4% to $120 million.

On a similar theme: Do You Debit or Credit Revenue to Increase It

AbbVie's financial performance is a story of growth and resilience. The company's oncology/hematology sales rose 12.9% to $1.69 billion in the quarter, beating the Zacks Consensus Estimate of $1.67 billion.

One of the key drivers of this growth was the performance of Elahere, an ovarian cancer drug acquired from ImmunoGen. Elahere generated revenues of $148 million, beating both the Zacks Consensus Estimate of $145 million and our model estimate of $146 million.

Broaden your view: Dcf Analysis Requires the Appraiser to Estimate

However, not all of AbbVie's oncology drugs performed well. Imbruvica, a leukemia drug marketed in partnership with Johnson & Johnson, saw its U.S. sales decline 8.6% to $625 million due to rising competition from novel oral treatments.

Venclexta, a leukemia drug marketed in collaboration with Roche, generated revenues of $655 million, reflecting 13% growth. This growth was slightly lower than expected, missing both the Zacks Consensus Estimate and our model estimate of $674 million.

AbbVie's adjusted earnings per share (EPS) also exceeded expectations, coming in at $2.46 and beating the guidance midpoint by $0.10. This was driven by strong top-line growth and effective cost management.

Here are some key financial highlights from AbbVie's first-quarter 2025 performance:

AbbVie's first-quarter performance was strong, with the company exceeding initial guidance and highlighting its ability to drive growth even post-Humira Loss of Exclusivity (LOE).

You might like: T Rowe Price Growth Stock Fund Class I

AbbVie's financial reporting is a key aspect to consider when evaluating the company's performance. The company's first-quarter 2025 results exceeded initial guidance, with adjusted earnings per share (EPS) of $2.46, surpassing the guidance midpoint by $0.10.

This solid performance was driven by strong top-line growth and effective cost management. AbbVie's total net revenues reached over $13.3 billion, surpassing expectations by nearly $550 million.

The company's ex-Humira platform delivered exceptional sales growth of over 21%, a testament to the successful transition and expansion of its next-generation assets. This growth is a key indicator of AbbVie's ability to drive revenue even post-Humira Loss of Exclusivity (LOE).

AbbVie's adjusted EPS guidance was raised by $0.10, now projecting between $12.09 and $12.29 for the full year. This increase reflects the company's confidence in its ability to maintain strong performance.

The company's full-year revenue guidance was also increased by $700 million to approximately $59.7 billion, reflecting an estimated 0.6% unfavorable impact from foreign exchange.

Here's a summary of AbbVie's key financial highlights: